A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Preclinical data and subset analyses from immunotherapy clinical trials indicate that prior radiotherapy was associated with better progression-free survival (PFS) and overall survival (OS) when combined with immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC). We present a prospective study of hypofractionated, image-guided radiation therapy (HIGRT) to a single site of metastatic disease concurrently with atezolizumab in patients with metastatic NSCLC. Patients meeting eligibility criteria received atezolizumab 1200mg IV every 3 weeks with concurrent 3- or 5-fraction HIGRT starting no later than the second cycle. The 3-fraction regimen employed a minimum of 8 Gy per fraction compared to 6 Gy for the 5-fraction regimen. Imaging was obtained every 12 weeks to assess response. From October 2015 to February 2017, 12 patients enrolled in the study (median age 64, range 55-77). The best response by RECIST criteria was partial response in 3 and stable disease in 3, for a disease control rate (DCR) of 50%. Five patients had a grade 3 immune-related adverse event (irAE), including choreoretinitis (n =1), pneumonitis (n=1), transaminitis (n=1), fatigue (n =1) and peripheral neuropathy (n=1). The median PFS was 2.3 months and the median OS was 6.9 months (range: 0.4-not reached). There was no clear association between peripheral blood T-cell repertoire characteristics at baseline, PD-L1, or tumor mutations and response or outcome. One long-term survivor exhibited oligoclonal T cell populations in a baseline tumor biopsy that were consistently detected in peripheral blood over the entire course of the study. HIGRT plus atezolizumab resulted in ORR of 25% and DCR of 50% in this pilot study. The incidence of grade 3 AEs was similar to that of atezolizumab alone. Though a pilot study with limited sample size, the results generated hypotheses worthy of further investigation.